Faizan Bashir: Exceptional Response to Pembrolizumab in Metastatic ER+/HER2− Breast Cancer

Faizan Bashir, Jr Researcher in Internal Medicine at Shiraz University of Medical Sciences, shared a post on LinkedIn:

“ER+/HER2− breast cancer has historically shown limited responsiveness to immune checkpoint inhibitors. This case, demonstrating an exceptional response to pembrolizumab in a patient with liver metastases, underscores that even within “immune-cold” tumors, unique biological subsets may derive significant benefit.

Check the full article.”

Title: Exceptional Response to Pembrolizumab in Metastatic ER+/HER2− Breast Cancer With Liver Metastases: A Case Report and Literature Review

Authors: Claudia Villa Celi, Supriya Peshin, Adit Dharia, Faizan Bashir, Linden Erica

Read Full Article.

You Can Also Read:

Pembrolizumab Based Chemo Immunotherapy Shows Promising Activity in Metaplastic Triple Negative Breast Cancer